Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449557 | 0.86 | NPC1 (0.47) | LCKMEN1KMT2AMAPTNPC1 | |
| SCHEMBL15610685 | 0.84 | KDM4E (0.54) | MEN1KMT2AMAPTNPC1POLB | |
| SCHEMBL29812173 | 0.79 | PLK1 (0.61) | MEN1KMT2AMAPTNPC1POLB | |
| SCHEMBL15610991 | 0.79 | PLK1 (0.61) | MEN1KMT2AMAPTNPC1POLB | |
| SCHEMBL678365 | 0.78 | LCK (0.53) | LCKKMT2APARP1ALDH1A1KDM4E | |
| SCHEMBL29745031 | 0.78 | LCK (0.53) | LCKKMT2APARP1ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL19584451 | 0.77 | LCK (0.51) | LCKKMT2APARP1ALDH1A1KDM4E | |
| SCHEMBL30853478 | 0.75 | CYP1A2 (0.51) | MAPTNPC1ALDH1A1HTTKDM4E | |
| SCHEMBL30748604 | 0.75 | RIPK1 (0.52) | NPC1POLBHTTRAB9AALOX15 | |
| SCHEMBL5173369 | 0.75 | LCK (0.56) | LCKKMT2APARP1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4182308-B1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-09-04 | — | — | EP | claimed |
| EP-4182308-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | claimed |
| EP-4126238-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE | Kinsensus Limited (GB) | 2023-02-08 | — | — | EP | claimed |
| EP-3999508-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-05-25 | — | — | EP | claimed |
| EP-1299387-A1 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2002004445-A1 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12115163-B2 | Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor | IDEAYA BIOSCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20230203029-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE | EVOTEC (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
| EP-4126238-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE | Kinsensus Limited (GB) | 2023-02-08 | — | — | EP | disclosed |
| EP-3999508-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114423757-A | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021198709-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE | KINSENSUS LIMITED (GB) | 2021-10-07 | — | — | WO | disclosed |
| WO-2020182076-A1 | USES OF PHOSPHODIESTERASE INHIBITORS | 南京药捷安康生物科技有限公司 | 2020-09-17 | — | — | WO | disclosed |
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
| CN-109575016-A | PDE9 inhibitors and uses thereof | 南京药捷安康生物科技有限公司 | 2019-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | LCK 483/4885MEN1 3343/4885KMT2A 3189/4885 |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | LCK 3112/4885MEN1 492/4885KMT2A 15/4885 |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | LCK 3112/4885MEN1 492/4885KMT2A 15/4885 |
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DKK1, WNT1 | LCK 412/4885MEN1 2685/4885KMT2A 1066/4885 |
| US-20230203029-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE | MERTK, AXL, TYRO3 | LCK 15/4885MEN1 703/4885KMT2A 2026/4885 |
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | DYRK1A, DKK1, WNT1 | LCK 412/4885MEN1 2685/4885KMT2A 1066/4885 |
| US-12115163-B2 | Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor | PRMT1, PRMT6, MAT2A | LCK 3112/4885MEN1 492/4885KMT2A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.